Table 2.
Multivariable Cox regression analysis, and event rates, on baseline IL‐18 (ng/L) and the primary composite outcome; CV death, sMI or stroke, during up to 1 year of follow‐up (n = 16 636)
| Model | IL‐18 level | No of events | No of patients | Event rate (%) | HR (95% CI) | P value |
|---|---|---|---|---|---|---|
| Model 1a | Continuous | 1424 | 16 636 | 8.6 | 1.05 (1.02‐1.07) | .0003 |
| Model 1b | <Q1: <180.0 | 331 | 4176 | 7.9 | .0179 | |
| Q1‐<Q2: 180.0‐237.0 | 346 | 4174 | 8.3 | 1.05 (0.91‐1.23) | ||
| Q2‐<Q3: 237.0‐311.0 | 346 | 4118 | 8.4 | 1.08 (0.93‐1.25) | ||
| ≥Q3: ≥ 311.0 | 401 | 4168 | 9.6 | 1.25 (1.08‐1.44) | ||
| Model 2a | Continuous | 1407 | 16 577 | 8.5 | 1.04 (1.02‐1.07) | .0017 |
| Model 2b | <Q1: <180.0 | 326 | 4161 | 7.8 | .0763 | |
| Q1‐<Q2: 180.0‐237.0 | 343 | 4162 | 8.2 | 1.06 (0.91‐1.24) | ||
| Q2‐<Q3: 237.0‐311.0 | 343 | 4102 | 8.4 | 1.11 (0.95‐1.30) | ||
| ≥Q3: ≥311.0 | 395 | 4152 | 9.5 | 1.21 (1.04‐1.41) | ||
| Model 3a | Continuous | 1380 | 16 139 | 8.6 | 1.03 (1.00‐1.05) | .0625 |
| Model 3b | <Q1: <180.0 | 313 | 4052 | 7.7 | .6527 | |
| Q1‐<Q2: 180.0‐237.0 | 338 | 4057 | 8.3 | 1.07 (0.92‐1.25) | ||
| Q2‐<Q3: 237.0‐311.0 | 338 | 4008 | 8.4 | 1.07 (0.92‐1.25) | ||
| ≥Q3: ≥311.0 | 391 | 4022 | 9.7 | 1.10 (0.95‐1.29) | ||
| Model 4a | Continuous | 1230 | 14 488 | 8.5 | 1.01 (0.98‐1.04) | .4085 |
| Model 4b | <Q1: <180.0 | 280 | 3660 | 7.7 | .9427 | |
| Q1‐<Q2: 180.0‐237.0 | 308 | 3685 | 8.4 | 1.05 (0.89‐1.24) | ||
| Q2‐<Q3: 237.0‐311.0 | 302 | 3598 | 8.4 | 1.02 (0.86‐1.20) | ||
| ≥Q3: ≥311.0 | 340 | 3545 | 9.6 | 1.03 (0.87‐1.21) |
Notes: Model 1 includes ln(IL‐18) and randomized treatment. Model 2 includes ln(IL‐18) and clinical variables. Model 3 includes the covariates from Model 2 and biomarkers: ln(cystatin C), ln(cTnT‐hs), ln(NT‐proBNP). Model 4 includes the covariates from Model 3 and biomarkers: ln(CRP), ln(GDF‐15), and ln(WBC).